NCT03222843View on ClinicalTrials.gov

Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient

PHASE3CompletedINTERVENTIONAL

Enrollment

424

Participants

Timeline

Start Date

June 30, 2017

Primary Completion Date

November 11, 2019

Study Completion Date

January 7, 2021

Conditions

Idiopathic Thrombocytopenic Purpura

Interventions

DRUG

Hetrombopag Olamine

once daily

DRUG

matching placebo

once daily

Trial Locations (3)

300041

Hospital of Blood Diseases, Chinese Academy of Medical Sciences, Tianjin

430022

Union Hospital Tongji Medical College Huazhong University of Science and technology, Wuhan

610041

West China Hospital，Sichuan University, Chengdu

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03222843 - Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient | Biotech Hunter | Biotech Hunter